Objective: To identify the importance of flow cytometry (FCM) in diagnosis and subclassifying acute lymphoblastic leukemia, and to highlight its capability to detect antigen aberration.
Introduction
Flow cytometry (FCM) is a lab technology that can define leukocyte surface proteins (antigens) using specific antibodies. These antibodies are given so-called CD numbers which stand for cluster of differentiation and refer to the group or cluster of antibodies all of which define a particular protein that differentiates cells of one type. More and more antigens are defined each year, and the CD numbers now range from CD1 through CD170.
(1,2) Antibodies against these antigens have allowed immunologists to define leukocytes that are microscopically indistinguishable from each other but whose concentrations vary in ways that are related to an individual's immune status. For example, B lymphocytes and T lymphocytes look identical under light microscope, but they possess different membrane proteins that allow them to be distinguished by specific antibody staining.(
1,2)
Some of the membrane antigens on leukocytes define function, some define lineage, and some define developmental stage. Flow cytometry can identify several cellular properties, including size, cytoplasmic and nuclear complexity. It can provide correlated data that links different population profiles all based on single cell analysis.
(1,2)
Flow cytometry is important diagnostic and prognostic modality for different hematologic malignancies including leukemias. Moreover, It can also be used to monitor the effectiveness of treatments and to detect minimal residual disease.
(3-9) In acute lymphoblastic leukemia, (FCM) can identify the lineage and stage of maturation using a panel of antibodies.
(5,10) The main goal of this study is to emphasize the importance of FCM as a tool for diagnosis andsubclassifying ALL cases and to demonstrate the frequency of different CD markers in both T-and B ALL patients at Kinfg Hussein Medical Center (KHMC).
Method
The flow cytometry results of one hundred and sixty five samples of bone marrow (BM) and/or peripheral blood (PB), diagnosed as de novo ALL were reviewed retrospectively. The initial FCM reports were obtained at time of diagnosis over a six year period between January 1 st 2006 and December 31 st 2011at King Hussein medical center (KHMC) in Jordan. The demographic information including age, gender was all noted. Acute leukemia diagnosis was established using conventional tools (PB and BM studies) using 20% blasts as a cut-off point for diagnosis. Bone marrow aspirate smears and peripheral blood specimens were obtained and processed using standard protocol by using Wright-Giemsa technique and visualized under light microscopy. The bone marrow biopsy specimens were fixed, stained, and processed using routine protocols for most cases.
(5)
Flow cytometry analysis using two-color instrument was performed using standard protocols. 
Results
A total of 165 cases were reviewed; 51 females and 114 males with a male to female ratio (M: F) of 2.2:1. The cases were divided according to gender and age group as shown by table 1. Of the total, 132 patients (80%) were of pre-B-ALL types, the M: F was 1.87:1 and most cases were within the pediatric-age group (2-15 years). Pre-T-ALL represented the minority of ALL cases with striking male predominance as M: F was 5.6:1, similar to pre-B-ALL; most cases were within the pediatric-age group (Table I) . The immunophenotypic pattern for pre-B-ALL cases (Table II) was as follows; 106 patients (87.6%) were [CD10/CD19] positive, 22 patients (16.6%) were CD19 positive, 125 patients represent (94.7%) were positive for cytCD79a, 126/129 (97.6%) were positive for HLA-DR, and 15 patients (11.36%) were CD10 negative. Aberrant myeloid antigens expression was noted; CD33 was positive in 15/113 (13.3%), whereas CD13 was lower with 2/108 (1.85%). The CD10 negative cases results were displayed on Table  III , two third of which are adults with equal M: F. All cases in this group were negative for myeloid and T-cell markers. The flow cytometry results for pre-T-ALL shown in Table IV were as follows: all cases were positive for cytCD3 and all were negative for B-cell markers (CD19, CD20, CD22 and cytCD79a). Myeloid markers results were as follows; 1/29 (3.4%) and 2/29 (6.9%) positive for CD33 and CD13 respectively. TdT marker positivity was traced in all cases, pre-B-ALL showed the higher percentage of positive cases of 98% (Fig. 1) . Moreover, help in differentiation acute myeloid leukemia (AML) from ALL and its subtypes, as well as revealing mixed-lineage leukemias subtypes. A distinct subtype of childhood T-cell ALL, termed early precursor T-cell ALL, which was identified by flow cytometry.
(9) It is characterized by a distinctive immunophenotype of CD1a and CD8 negativity, with weak expression of stem cell or myeloid markers and weak expression of CD5.
(11) A retrospective analysis suggested that this subset may have a poorer prognosis than other cases of T-cell ALL.
(12)
According to WHO classification, the presence of myeloperoxidase (MPO) is required to establish the myeloid lineage. An ambiguous lineage represents less than 5% of acute leukemia in children, expressing features of myeloid and lymphoid lineage (13_15). Expression of aberrant myeloid antigens reportedly occurs in 5-22% of pediatric patients with de novo ALL.
(15) Our study showed pre-B-ALL co-expressing myeloid markers CD13 and CD33 of 15/165 patients (9.1%) of total ALL cases, and 15/132 (11.3%) respectively. Precursor B-cell ALL, defined by the expression of cytoplasmic CD79a, CD19, HLA-DR, and other B cell-associated antigens, accounts for 80% to 85% of childhood ALL. Approximately 90% of precursor B-cell ALL cases expresses the CD10 surface antigen. We found 15/132 patients (11.36%) pre-B-ALL CD10 negative in our study, which still within the wide international range 5% to 20%. (16) A large study has been performed in Japan by Pediatric Leukemia/Lymphoma Study Group (7) Shows that B-lineage and T-ALL responsible for 87 and 13 % of childhood ALL patients, respectively. More than 90% of early pre-B ALL cases pressed CD19, CD79a, CD22, CD10 and TdT. Cytoplasmic CD3 and CD7 antigens were positive in all T-ALL specimens. More than 80% of T-ALL cases expressed CD2, CD5 and TdT. We showed almost similar results for both B-and T-ALL except for CD5 where less than 40% of our T-ALL cases showed positive expression. Further study to include more sample number and to figure out clinicopathological correlation is needed in our patients to find out this deviation. Regarding expression of CD13 and CD33 was significantly more frequently associated with B-ALL than with T-ALL which supports our results.
Recommendations
A Consensus acute leukemia and ALL panels should be adopted as a routine standard of care in our lab. Well-defined guidelines and algorithm should be implemented and standardized throughout all hematology laboratories worldwide.
Limitations of the Study
We did not look into the survival rate and its relation to various immunophenotypic findings, as well as the use of two color flow cytometry,both represent limitations in our study.
Conclusion
Flow cytometry is a golden tool in diagnosis and identifying ALL subtypes. Precursor-Bacute lymphoblastic leukemia represents most of ALL cases with minority of cases with CD10negative. Myeloid antigen expression would not change the diagnosis of ALL in either B-or T-subtypes. Further clinical correlation is needed to figure out aberrant markers prognostic implications.
